Immunotherapy Biotech Genocea Closes Down As Sector Slump Deepens
Second Closure Of 2022
Executive Summary
The neoantigen immunotherapy company is a casualty of slow R&D progress and a squeeze on biotech finance – and more firms are in the firing line.
You may also be interested in...
Clovis Close To Bankruptcy As Cancer Drug Outlook Worsens
Troubles are mounting for Clovis and its PARP inhibitor Rubraca, and now the company looks to be just months from bankruptcy.
4D Pharma Is Latest Biotech Casualty After Creditor Calls Time
The UK biotech looks to have reached the end of the road, despite some encouraging signs from its microbiome-based pipeline.
Vertex Spots Potential Bargain Of $60m Entry Into Complement Regulation
Vertex has acquired the full assets to a promising protease-based drug platform from Catalyst, broadening its R&D base once again.